Combined Analysis of Phase III Trials Evaluating [(99m)Tc]Tilmanocept and Vital Blue Dye for Identification of Sentinel Lymph Nodes in Clinically Node-Negative Cutaneous Melanoma

Documenti analoghi

• Comparative Evaluation of [(99m)Tc]Tilmanocept for Sentinel Lymph Node Mapping in Breast Cancer Patients: Results of Two Phase 3 Trials
  di: Wallace, Anne M., et al.
  Pubblicazione: (2013)
• A Phase 2 Study of (99m)Tc-Tilmanocept in the Detection of Sentinel Lymph Nodes in Melanoma and Breast Cancer
  di: Leong, Stanley P. L., et al.
  Pubblicazione: (2011)
• Who Is to Blame for False-Negative Sentinel Node Biopsies in Melanoma?
  di: Sondak, Vernon K., et al.
  Pubblicazione: (2009)
• Sentinel lymph node detection in oral cancer: a within-patient comparison between [(99m)Tc]Tc-tilmanocept and [(99m)Tc]Tc-nanocolloid
  di: den Toom, Inne J., et al.
  Pubblicazione: (2020)
• Optimal efficient imaging time for identification of sentinel lymph node with Tc-99m Tilmanocept in breast cancer patients
  di: Baldeosingh, Sacha C, et al.
  Pubblicazione: (2020)